Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: The Fox who wrote (2117)	2/27/2002 4:52:23 PM
From: Cacaito	Respond to of 2515

Gw and The Fox would like whatever as you pleased, but the bottomline is the CURRENT regulations, and your views about anarchy drug use is fine until a Rezulin or a Redux comes around THEN, YOU ARE BLAMING the Fda for not keeping those dangers out of the market sooner. Mold the situation to your needs/views of the moment. You are not only wrong about the supposed "non toxic, non harming" nature of the ideal drug you are talking about, there are other BIG problems: cost, who will pay for it (not WSJ), drug interactions, inability to enroll subjects in trials of appropriately study drugs (due to inclusion/exclusion) criteria, false hopes... Just the problem of getting more difficult problems with other drug trials is a HUGE complication from a let anything go system. Just look how a well tested drug like Irinotecan complicated the Erbitux trial to the point of worthlessness (it is worthless data). Imcl was given the TRUST of the public via the Fda and the least they did was to mismanage it. Anyone believing the "leak" is the source of the problem, wrong decisions will follow that believe.